Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VX-433 and Its Effects on the Pharmacokinetics of Midazolam and Bupropion

NCT07584434 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.

NCT NCT07584434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07584434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VX-433 and Its Effects on the Pharmacokinetics of Midazolam and Bupropion
Lead sponsor
Vertex Pharmaceuticals Incorporated
Phase
Phase 1
Overall status
Recruiting
Start date
May 21, 2026
Completion date
March 5, 2027
Enrollment
118 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

narcolepsy type 1 (nt1)